Roche Holding AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0QQ6.L | NVS | EXEL | ONCY | BIIB | RCUS | |
|---|---|---|---|---|---|---|
| Market cap | — | 297.02B | 16.18B | 65.59M | 37.51B | 2.43B |
| P/E (TTM) | 24.6 | 23.3 | 20.4 | — | 45.1 | — |
| Forward P/E | — | 15.9 | 15.3 | -2.5 | 15.4 | -6.2 |
| Price/book | 9.7 | 7.1 | 8.8 | -10.2 | 2.0 | 5.3 |
| Dividend yield | 2.46% | 3.08% | — | — | — | — |
| 1-year change | −9.24% | +16.93% | +69.72% | −56.78% | +60.57% | +13.83% |
| Today | 0.00% | +1.52% | +1.13% | −2.19% | +5.34% | +1.36% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0QQ6.L news ›Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma Sales
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Roche Q3 results beat on revenue, though pharma sales a slight miss
Roche Q3 results beat revenue estimates and reaffirmed guidance as key drug sales rose. Read more here. Roche's (RHHBY) Q3 financial results beat on the top line, though pharma sales just missed expectations. Revenue of CHF16.13B ($19.61B)…
Roche Holding AG (RHHBY) Q3 2026 Sales/ Trading Statement Call - Slideshow
2026-10-22. The following slide deck was published by Roche Holding AG in conjunction with this event. The following slide deck was published by Roche Holding AG in conjunction with this event.
Roche posts higher sales on growth scross pharma, diagnostics units
Roche Holding reported higher sales for the third quarter on growth in its pharmaceuticals and diagnostics units, as the drugmaker works to secure approval for its new breast-cancer and multiple-sclerosis pills. The Swiss group said…
Roche beats revenue estimates, shares slip as copycats eat into Xolair sales
By Patrick Wingrove and Marleen Kaesebier Group revenue rose 7% at constant exchange rates to 16.13 billion Swiss francs ($19.61 billion), exceeding a company-compiled consensus forecast of 15.75 billion francs ($19.15 billion). But the…
Roche offers $15bn for strategic-level deal with Hansoh
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger. The latest – which includes an upfront fee of $400 million and potentially more than $15…
Roche posts solid results ahead of looming patent cliff
Roche's pharma sales rose a healthy 7% in the third quarter, although the first signs of weakness for blockbuster immunology product Xolair are a warning of tougher times ahead. Roche's drugs business brought in CHF 11.47 billion (nearly…
One pill a day, 30% fewer relapses: Roche's big breast cancer gamble faces US FDA
Swiss pharma giant Roche has a daily breast cancer pill in front of the US Food and Drug Administration, and a verdict is close. The drug, giredestrant, is still experimental, and no regulator has cleared it anywhere – what is known about…
Roche CEO slams European drug policy: Europe is “playing not to lose”
Chef for Kvalitet og Compliance Manager, Corporate Affairs, Denmark & Norway Senior Drug Product Filling Specialist Global Regulatory Strategy Lead, Senior Director Head of Medical Affairs International Markets Senior Drug Substance…
Roche third quarter sales slightly beat expectations with growth across divisions
ZURICH/ LONDON, Oct 22 - Roche sales rose in the third quarter, the Swiss drugmaker said on Thursday, slightly beating analyst expectations. With growth in both its pharmaceuticals and diagnostics divisions, group sales came in…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com19
-
seekingalpha.com9
-
openpr.com8
-
tradingview.com8
-
freedom959.net7
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.